New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for ...

New study results presented at the European Lung Cancer Congress, ELCC, 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s (AZN) ...

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer ...

New study results have shown the role of AstraZeneca’s Tagrisso (osimertinib) as monotherapy and as the backbone for novel combinations across stages and settings of epidermal growth factor ...

AstraZeneca’s Tagrisso can be used alongside chemotherapy as a frontline therapy for EGFR-positive non-small cell lung cancer (NSCLC), according to the FDA, consolidating its position as the ...

AstraZeneca has received two separate recommendations from England’s National Institute for Health and Care Excellence (NICE) for the use of its lung cancer treatments, Tagrisso (osimertinib ...

TAGRISSO is a prescription medication for adults with non-small cell lung cancer (NSCLC) that carries specific EGFR gene mutations. It is used to help prevent cancer recurrence after surgical ...

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

We are the problem when we would rather take the injection or the pill than make the lifestyle change. I am fortunate that I ...